Insulin analogues: Searching for a physiological replacement;Análoges de insulina: En búsqueda del reemplazo fisiológico

Revista Medica de Chile

Volumn 134, Issue 2, 2006, Pages 239-250

  Francisca Eyzaguirre, C ^a   Codner, Ethel ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Diabetes mellitus, insulin dependent; Insulin; Insulin, long acting; Pro insulin

Indexed keywords

DRUG DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLULISINE; INSULIN LISPRO; INSULIN, ASP(B28)-;

DIABETES MELLITUS; HUMAN; REVIEW; SECRETION;

DIABETES MELLITUS; HUMANS; INSULIN;

EID: 33645072458     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
2. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
3. HIRSCH IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998; 82: 689-719.
4. AYLWIN C, CODNER E, GARCÍA H, PÉREZ J, UGARTE F, ESCOBAR M ET AL Protocolo AUGE. Diabetes Mellitus tipo 1. Santiago: Ministerio de Salud de Chile; 2004.
5. CODNER E, MERICQ V, GARCÍA H, LÓPEZ C, CÁCERES J, GAETE X ET AL Resultados de un programa multidisciplinario de tratamiento intensificado de la Diabetes Mellitus tipo 1 (DM1) en un Hospital Público. Rev Méd Chile 2003; 131: 857-64.
6. CODNER E, MERICQ MV, ROMAN R, HRUC I, MARTÍNEZ A, UNANUE N ET AL Nuevos esquemas de tratamiento con insulina en niños y adolescentes con Diabetes Mellitus tipo 1 (DM1) en un Hospital Público. Rev Chil Pediatr 2004; 75: 520-9.
7. BOLLI GB, DIMITRIADIS GD, PEHLING GB, BAKER BA, HAYMOND MW, CRYER PE ET AL. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 1706-11.
8. CIOFETTA M, LALLI C, DEL SINDACO P, TORLONE E, PAMPANELLI S, MAURO L ET AL Contribution of postprandial versus interprandial blood glucose to HbAlc in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.
9. BURGE MR, SCHADE DS. Insulins. Endocrinol Metab Clin North Am 1997; 26: 575-98.
10. DEL SINDACO P, CIOFETTA M LALLI C, PERRIELLO G, PAMPANELLI S, TORLONE E ET AL. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15: 592-600.
11. DIMITRIADIS GD, GERICH JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-7.
12. HEINEMANN L, RICHTER B. Clinical pharmacology of human insulin. Diabetes Care 1993; 16 Suppl 3: 90-100.
13. HEINEMANN L, CHANTELAU EA, STARKE AA Pharmaco-kinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. Diabete Melab 1992; 18: 21-4.
14. STANDL E. Insulin analogues - state of the art. Harm Res 2002; 57 Suppl 1: 40-5.
15. HOLLEMAN F, HOEKSTRA JB. Insulin lispro. N Engl J Med 1997; 337: 176-83.
16. WILLIAMS KM, DUNGER DB. Insulin treatment in children and adolescents. Acta Paediatr 2004; 93: 440-6.
17. SLIEKER LJ, BROOKE GS, CHANCE RE, AE E. Insulin and IGF-1 analogs: novel approaches to improved insulin pharmacokinetics. En: Le Roith D, M.K. R, eds. Current directions in insulin-like growth factor research. New York: Plenum Press, 1994; 25-32.
18. CISZAK E, BEALS JM FRANK BH, BAKER JC, CARTER ND, SMITH GD. Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. Structure 1995; 3: 615-22.
19. HOWEY DC, BOWSHER RR, BRUNELLE RL, WOODWORTH JR [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
20. ANDERSON JH JR, BRUNELLE RL, KOIVISTO VA, PFUTZNER A TRAUTMANN ME, VIGNATI L ET AL. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-70.
21. TER BRAAK EW, WOODWORTH JR, BLANCHI R, CERIMELE B, ERKELENS DW, THIJSSEN JH ET AL Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-40.
22. HEINEMANN L, HEISE T, WAHL LC, TRAUTMANN ME, AMPUDIA J, STARKE AA ET AL Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996; 13: 625-9.
23. TUOMINEN JA KARONEN SL, MELAMIES L, BOLLI G, KOIVISTO VA. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetotogia 1995; 38: 106-11.
24. EBELING P, JANSSON PA SMTTH U, LALLI C, BOLLI GB, KOIVISTO VA. Strategies toward improved control during insulin lispro therapy in IDDM Importance of basal insulin. Diabetes Care 1997; 20: 1287-9.
25. DEEB LC, HOLCOMBE JH, BRUNELLE R, ZALANT S, BRINK S, JENNER M ET AL.Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001; 108: 1175-9.
26. CHASE HP, LOCKSPEISER T, PEERY B, SHEPHERD M, MACKENZIE T, ANDERSON J ET AL The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 430-4.
27. RD, STUART CA, BRODOWS RG, SCHWARTZ S, GRAF CJ, ZAGAR A ET AL Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbAlc. IOEZ Study Group. Diabetes Care 2000; 23: 1236-41.
28. BOLLI GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2: S317-332.
29. FINEBERG NE, FINEBERG SE, ANDERSON JH, BIRKETT MA, GIBSON RG, HUFFERD S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-4.
30. LOUKOVAARA S, IMMONEN I, TERAMO KA, KAAJA R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003; 26: 1193-8.
31. BOSKOVIC R, FEIG DS, DEREWLANY L, KNIE B, PORTNOI G, KOREN G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003; 26: 1390-4.
32. PLANK J, WUTTE A, BRUNNER G, SIEBENHOFER A, SEMLITSCH B, SOMMER R ET AL A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25: 2053-7.
33. HEINEMANN L, WEYER C, RAUHAUS M, HEINRICHS S, HEISE T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-4.
34. MORTENSEN HB, LINDHOLM A, OLSEN BS, HYLLEBERG B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000; 159: 483-8.
35. DEVRIES JH, LINDHOLM A, JACOBSEN JL HEINE RJ, HOME PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med 2003; 20: 312-8.
36. REYNOLDS NA, WAGSTAFF AJ. Insulin Aspart A Review of its Use in the Management of Type 1 or 2 Diabetes Mellitus. Drugs 2004; 64: 1957-74.
37. HOME PD, LINDHOLM A, HYLLEBERG B, ROUND P. Improved glycemic control with insulin aspart a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904-9.
38. HERMANSEN K, FONTAINE P, KUKOLJA KK, PETERKOVA V, LETH G, GALL MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-9.
39. DANNE T, AMAN J, SCHOBER E, DEISS D, JACOBSEN JL FRIBERG HH ET AL A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 2359-64.
40. YASUDA H, NAGATA M, MORIYAMA H, FUJIHIRA K, KOTANI R, YAMADA K ET AL. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24: 2008-9.
41. POULSEN MK, HENRIKSEN JE, HOTHER-NIELSEN O, BECKNIELSEN H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003; 26: 3273-9.
42. BARLOCCO D. Insulin glulisine. Aventis Pharma. Curr Opin Investig Drugs 2003; 4: 1240-4.
43. DAILEY G, ROSENSTOCK J, MOSES RG, WAYS K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-8.
44. AVENUS PHARMACEUTICALS INT. Apidra (insulin glulisine [rDNA origin] injection). Rev April 2004a.
45. PERRIELLO G, DE FEO P, TORLONE E, FANELLI C, SANTEUSANIO F, BRUNETTI P ET AL. The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetola gia 1991; 34: 21-8.
46. SCOTT S, FISHER A Studies on insulin with protamine. J Pharmacol Exp Ther 1936; 58.
47. HALLAS-MOLLER K, JERSILD M, PETERSEN K, SCHLICHTKRULL J. Cinical studies on new insulin preparations with prolonged action; one daily injection with insulin zinc preparations. Ugeskr Laeger 1951; 113: 1767-71.
48. STARKE AA HEINEMANN L, HOHMANN A, BERGER M The action profiles of human NPH insulin preparations. Diabet Med 1989; 6: 239-44.
49. LEPORE M, PAMPANELLI S, FANELLI Q PORCELLATI F, BARTOCCI L, DI VINCENZO A ET AL. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-8.
50. BOLLI GB, PERRIELLO G, FANELLI CG, DE FEO P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 1993; 16 Suppl 3: 71-89.
51. HEISE T, NOSEK L, RONN BB, ENDAHL L, HEINEMANN L, KAPITZA C ET AL Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-20.
52. DANNE T, LUPKE K, WALTE K, VON SCHUETZ W, GALL MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003; 26: 3087-92.
53. GILLIES PS, FIGGITT DP, LAMB HM Insulin glargine. Drugs 2000; 59: 253-60.
54. KAPLAN W, RODRÍGUEZ LM, SMITH OE, HAYMOND MW, HEPTULLA RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004; 27: 2739-40.
55. HEINEMANN L, LINKESCHOVA R, RAVE K, HOMPESCH B, SEDLAK M, HELSE T. Time-action profile of the long-acting insulin analog insulin glaigine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-9.
56. HAMANN A, MATTHAEI S, ROSAK C, SILVESTRE L A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-44.
57. TAN CY, M WILSON D, BUCKINGHAM B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004; 5: 80-6.
58. CHASE HP, DIXON B, PEARSON J, FIALLO-SCHARER R, WALRAVENS P, KLINGENSMITH G ET AL Reduced hypoglycemic episodes and improved glycemie control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003; 143: 737-40.
59. MURPHY NP, KEANE SM ONG KK, FORD-ADAMS M, EDGE JA, ACERIM CL ET AL Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799-804.
60. RATNER R, HIRSCH I, NEIFING J, GARG S, MECCA T, WILSON C. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-43.
61. ROSSETTI P, PAMPANELLI S, FANELLI C, PORCELLATI F, COSTA E, TORLONE E ET AL Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-6.
62. WEINTROB N, BENZAQUEN H, GALATZER A, SHALITIN S, LAZAR L, FAYMAN G ET AL Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003; 112: 559-64.
63. GOONETILLEKE R, POLLITZER M, MANN N. Insulin for toddlers with difficult diabetes. Diabetes Care 2004; 27: 1505.
64. HEINEMANN L, SINHA K, WEYER C, LOFTAGER M, HIRSCHBERGER S, HEISE T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Din bet Med 1999; 16: 332-8.
65. VAGUE P, SELAM JL, SKEIE S, DE LEEUW I, ELTTE JW, HAAHR H ET AL Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus legimen with premeal insulin aspart Diabetes Care 2003; 26: 590-6.
66. HIRSCH IB, FARKAS-HIRSCH R, SKYLER JS. Intensive insulin therapy for treatment of type I diabetes. Diabetes Care 1990; 13: 1265-83.
67. LALLI C, CIOFETTA M, DEL SINDACO P, TORLONE E, PAMPANELLI S, COMPAGNUCCI P ET AL. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-77.
68. FRANZ MJ, BANTLE JP BEEBE CA, BRUNZELL JD, CHLASSON J-L, GARG A ET AL Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care 2002; 25: 148-98.
69. RABASA-LHORET R, GARON L LANGELIER H, POISSON D, CHIASSON JL Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care 1999; 22: 667-73.
70. WEISSBERG-BENCHELL J, ANTISDEL-LOMAGLIO J, SESHADRI R Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-87.